Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is Biogen a Buy?

TheMotleyFool

0 0

Over the past three years, Biogen (NASDAQ: BIIB) stock has taken investors on the ride of a lifetime. Shares have consistently oscillated between over $360 a share to near $200 levels.

As it turns out, investors are heavily betting on the potential for its Alzheimer's disease therapy, aducanumab, to reach commercialization. Can Biogen successfully roll out a treatment to better help patients in a market estimated to reach nearly $5.7 billion by 2027?

Image source: Getty Images.

Source Fool.com

Like: 0

BIIB

Teilen